Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
McKinsey
Moodys
Express Scripts
Johnson and Johnson

Last Updated: August 17, 2022

AUGMENTIN XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Augmentin Xr, and when can generic versions of Augmentin Xr launch?

Augmentin Xr is a drug marketed by Us Antibiotics and is included in one NDA.

The generic ingredient in AUGMENTIN XR is amoxicillin; clavulanate potassium. There are forty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.

Drug patent expirations by year for AUGMENTIN XR
Drug Prices for AUGMENTIN XR

See drug prices for AUGMENTIN XR

Recent Clinical Trials for AUGMENTIN XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GlaxoSmithKlinePhase 2
The University of Hong KongPhase 4
Queen Mary Hospital, Hong KongPhase 4

See all AUGMENTIN XR clinical trials

Paragraph IV (Patent) Challenges for AUGMENTIN XR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
AUGMENTIN XR Extended-release Tablets amoxicillin; clavulanate potassium 1000 mg/62.5 mg 050785 1 2009-01-21

US Patents and Regulatory Information for AUGMENTIN XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Us Antibiotics AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AUGMENTIN XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Us Antibiotics AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 See Plans and Pricing See Plans and Pricing
Us Antibiotics AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 See Plans and Pricing See Plans and Pricing
Us Antibiotics AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 See Plans and Pricing See Plans and Pricing
Us Antibiotics AUGMENTIN XR amoxicillin; clavulanate potassium TABLET, EXTENDED RELEASE;ORAL 050785-001 Sep 25, 2002 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for AUGMENTIN XR

See the table below for patents covering AUGMENTIN XR around the world.

Country Patent Number Title Estimated Expiration
Belgium 1012733 FORMULATIONS PHARMACEUTIQUES NOUVELLES COMPRENANT L'AMOXYCILLINE ET DU CLAVULANATE DE POTASSIUM. See Plans and Pricing
Poland 197448 See Plans and Pricing
China 100382782 See Plans and Pricing
Malaysia 119953 NOVEL METHOD OF TREATMENT See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Mallinckrodt
Boehringer Ingelheim
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.